Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

on at www.provenge.com or call Dendreon ON Call at 1-877-336-3736

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics.  The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types.  Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.  The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN.  For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.  Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release.
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company ... at three investor conferences: , Wednesday, September 9 ... New York at the New York ... at the BioCentury NewsMakers Conference in New York ... , Thursday, September 17 at 9:30 AM at the ...
(Date:9/2/2015)... LIBERTYVILLE, Ill. (PRWEB) , ... ... ... a leading provider of regulatory compliance, quality systems, analytical testing, education and ... consulting firm with expertise in medical device products/processes development, design control, validation, ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... SAN RAMON, Calif., Aug. 7 Odyssey Thera, ... from Pfizer Inc, following,Pfizer,s decision to progress a ... candidate was extensively studied by,Odyssey Thera as part ... are very pleased with the progress of the ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin Board: CHBT), ... manufacture, marketing and distribution of,probiotics dietary supplements, today ... a.m. EDT on Friday, August 15, 2008, to ... ended June 30, 2008, of its fiscal,2009., ...
... SCOLR Pharma, Inc.,(Amex: DDD ) today reported ... 30, 2008. The Company will host a live conference ... Time)., Daniel O. Wilds, SCOLR Pharma,s President and ... during the second quarter,maintaining a sharp focus on advancing ...
Cached Biology Technology:China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 2China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 7
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... For nearly half a century, scientists have been trying ... reasonably sized X-ray laser that could, among other things, ... decades, University of Colorado at Boulder physics professors Margaret ... that goal. Recent breakthroughs by their team at ...
... arrhythmia a chronic irregularity of heartbeat which ... the condition is not acutely life-threatening, it does increase ... cardiac insufficiency, stroke and dementia. In the third of ... of researchers, led by LMU physician PD Dr. Stefan ...
... world,s population will swell to 9 billion people by ... to provide enough food to meet demand, says University ... Branen, a University of Idaho food scientist, organized a ... Science annual meeting Sunday to explore ways biotechnology could ...
Cached Biology News:CU physicists use ultra-fast lasers to open doors to new technologies unheard of just years ago 2CU physicists use ultra-fast lasers to open doors to new technologies unheard of just years ago 3When the heart gets out of step 2When the heart gets out of step 3Biotech, nanotech and synthetic biology roles in future food supply explored 2
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... ProteomeLab PA 800 is an automated, ... of Beckman Coulters ProteomeLab family of ... comprehensive range of automated protein characterization ... mapping, isoelectric focusing, carbohydrate profiling and ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: